Skip to main content

Seelos Therapeutics, Inc.

SEELDelisted Apr 4, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001017491

Seelos Therapeutics, Inc. was delisted on Apr 4, 2025; its insiders filed their last Form 4 on Mar 1, 2024; 23 institutions reported holding it in 13F filings for Q2 2024, worth $129.4K in total; no superinvestor held it.

13F holders, Q2 2022

Institutional positions in Seelos Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
86
−2 vs. Q1 2022
Shares held
31.3M
−8.03M (−20.4%) vs. Q1 2022
Total value
$21.3M
−$11.6M (−35.2%) vs. Q1 2022
New holders
20
19 more added
Sold out
22
29 more reduced

4 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting SEEL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2022: 86 institutions
Q1 2021: 73 institutionsQ2 2021: 105 institutionsQ3 2021: 110 institutionsQ4 2021: 97 institutionsQ1 2022: 92 institutionsQ2 2022: 86 institutionsQ3 2022: 85 institutionsQ4 2022: 80 institutionsQ1 2023: 80 institutionsQ2 2023: 83 institutionsQ3 2023: 82 institutionsQ4 2023: 39 institutionsQ1 2024: 36 institutionsQ2 2024: 23 institutionsQ3 2024: 15 institutionsQ4 2024: 3 institutionsQ1 2025: 1 institutionQ2 2025: 1 institutionQ3 2025: 1 institutionQ4 2025: 1 institutionQ1 2026: 1 institutionQ2 2026: 0 institutions
Value heldQ2 2022: $21.3M
Q1 2021: $124.8MQ2 2021: $107.8MQ3 2021: $98.2MQ4 2021: $65.9MQ1 2022: $33.0MQ2 2022: $21.3MQ3 2022: $28.0MQ4 2022: $15.6MQ1 2023: $15.1MQ2 2023: $27.1MQ3 2023: $7.01MQ4 2023: $2.48MQ1 2024: $1.55MQ2 2024: $129.4KQ3 2024: $145.2KQ4 2024: $4.77KQ1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding SEEL and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20261$0
Q4 20251$0
Q3 20251$0
Q2 20251$0
Q1 20251$0
Q4 20243$4.77K
Q3 202415$145.2K
Q2 202423$129.4K
Q1 202436$1.55M
Q4 202339$2.48M
Q3 202382$7.01M
Q2 202383$27.1M
Q1 202380$15.1M
Q4 202280$15.6M
Q3 202285$28.0M
Q2 202286$21.3M
Q1 202292$33.0M
Q4 202197$65.9M
Q3 2021110$98.2M
Q2 2021105$107.8M
Q1 202173$124.8M

Institutions, Q2 2022

Shares, value and share of portfolio for each institution holding Seelos Therapeutics, Inc.; share changes are against Q1 2022.

Institutions holding SEEL in Q2 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Principal Financial Group Inc0$00.00%−29,894−100.0%Sold out
Boothbay Fund Management, LLC0$00.00%−24,378−100.0%Sold out
Truist Financial Corp0$00.00%−22,116−100.0%Sold out
ProShare Advisors LLC0$00.00%−18,419−100.0%Sold out
Barclays PLC0$00.00%−15,948−100.0%Sold out
Amalgamated Bank0$00.00%−15,994−100.0%Sold out
Ameritas Investment Partners, Inc.0$00.00%−5,944−100.0%Sold out
Ellevest, Inc.0$00.00%−254−100.0%Sold out
WealthPLAN Partners, LLC––––Not filed
WealthPlan Investment Management, LLC––––Not filed
Amalgamated Financial Corp.––––Not filed
Nauset Wealth Management. LLC––––Not filed